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did not differ between the studied groups, but proportion of
hypertension among controls was higher compared to the
patients with CRC (85.3% vs 69.6% p = 0.002).
Conclusions: In studied sample, we did not found the differ-
ences in the values of anthropometric indicators of metabolic
syndrome, cholesterol, HDL cholesterol, triglycerides and glucose
between patients with colorectal cancer and control. Systolic and
diastolic blood pressure as well as hypertension frequency were
significantly lower in CRC group than in the control group. Fur-
ther analysis including stage and localization of CRC is required.
The HAPIEE project is supported by Wellcome Trust
(WT081081AIA).
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The purpose of the study was to access pattern of microRNA
expression in tissue of precancerous lesions and larynx cancer.
A total of 25 people with a diagnosis of dysplasia II–III (n = 10),
control group (dysplasia 0, n = 15) and larynx cancer patients
(n = 46) were examined. Fresh frozen biopsies and adjacent nor-
mal epithelium were used. The diagnosis was verified by histol-
ogy. All qRT-PCR data were analyzed using the Pfaffl analysis.
Multiplex RT-PCR on miRNA templates were performed as
described by Chen et al. (2005). TaqMan miRNA assays (Iyevleva
et al., 2012) were used to quantify expression of mature miRNAs
of interest (miR-18a, -21, -155, -200a, -200c, -205, -221, -494). Data
were analyzed using Welsh t-test with a 5% FDR correction.
According to our results, aberrant expression of some miRNAs
was showed. There was no significant differences in miRNA
expression in a total group (n = 25) although a trend towards over-
expression of oncogenic miRNA-21 and -155 according to severity
of dysplastic changes in a tissue were present. Detailed analysis
showed significant overexpression of that miRNAs as well as
miRNA-200c and -205 in a group of dysplasia II- III against control
group (15 vs 10, p = 0.019, p = 0.045 and p = 0.020, p = 0.038, respec-
tively) but these results did not meet 5% FDR correction.
Data showed overexpression of the same microRNA (-205,
-155, -200 and -21) in larynx cancer patients compared to control
group (46 vs 15, p = 0.0002, p = 0.008, p = 0.009, p = 0.013, respec-
tively). It should be pointed that microRNA pattern both in larynx
cancer and patients with dysplasia II-III was very close showing
similarity of these groups at molecular level. Frequency of cases
with microRNA-205 overexpression was 2.98 times higher in can-
cer patients than in those who had no malignant transformation
(CI 95%, 1.41–16.26, p = 0.007). Data showed that up regulation of
microRNA-205 could be a marker of disease progression
(OR = 4.79). Three other microRNAs did not show any promising
results as biomarkers of cancer progression but data obtained
has interesting fundamental value.
These miRs (-21, -155, -205 and -200c) are known to be regula-
tors of processes that play an emergent role in carcinogenesis and
our results obtained in vivo highlight and expand knowledge
about some aspects of larynx cell transformation. Data suggest
that miRNAs changing its expression according to dysplasia
progress and could be important players in complex process of
carcinogenesis as well as could be potential markers of disease
progression.
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The purpose of the study was to assess parameters of
local cellular immunity, expression of apoptosis-controlling
proteins and some other receptors in various molecular sub-
types of breast cancer (BC) with different clinical course and
prognosis.
Materials and methods: 100 BC patients aged 30–76 years (59
± 3.4) were recruited. Tissues of tumor and peritumoral area were
homogenized by MediMachine, subset contents of T, B,
NK-lymphocytes were estimated by flow cytometer FACS CantoII.
Percentage of lymphocytes expressing CD3, CD4, CD8, CD19,
CD16/56, were counted from total amount of CD45+ lymphocytes.
Sections of paraffin-embedded blocks were studied by immuno-
histochemical method with polyvalent HRP-DAB detection sys-
tem. Staining was performed using Thermo Scientific
autostainer. Tumor was considered p53-positive when >25% of
tumor cell nuclei were positively stained, and bcl-2-positive when
>25% of cells showed specific cytoplasmic staining. Expression of
E-cadherin was assessed by the number of cells with positive
membrane expression of this marker, taking into account inten-
sity of the reaction. Expression of topoisomerase 2a and androgen
receptors was assessed by the number of tumor cells with
positive nuclear expression of these markers; number of stained
nuclei per 100 nuclei in 3 fields of view was counted.
Results: Some differences characterizing tumor cells of molec-
ular breast cancer subtypes were found. Tumor tissue contained
higher amount of T-lymphocytes than blood (85.9 ± 2.36% vs
60.1 ± 4.5%, P < 0.05) predominantly CD3+CD8+ cells (34.0 ± 1.9%
vs 20.3 ± 5.36%, P < 0.05) but lower percentage of B- and
NK-cells. In tissue of peritumoral area amounts of CD3+ and
CD3+CD8+ cells were also higher, while CD19+ level was lower
than in blood. In the same samples content of CD3+CD4+ was
lower and amount of NK-cells was higher than in tumor tissue.
Triple- negative subtype was characterized by maximal content
of CD3+ lymphocytes (92.2 ± 1.4%), luminal A contained the high-
est amount of CD3+CD16/56+ cells (10.6 ± 1.73%) vs luminal B
(4.34 ± 1.27%) and triple-negative (4.13 ± 1.63%). Her2+ neu BC
demonstrated high amount of NK-cells in peritumoral area but
not in tumor.
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